Ancora provides an AI-driven platform that matches cancer patients with relevant clinical trials based on their diagnosis, location, and preferences. Users can quickly search, refine results through a brief questionnaire, and track enrollment progress within a secure, HIPAA- and GDPR-compliant dashboard. The service is free, offering personalized trial alerts and the ability to share profiles with trial sites while maintaining strict privacy controls.
Funding
$520K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patient enrollment in clinical trials is often slow and inefficient due to difficulties in matching eligible patients with suitable studies. Many trials face delays or even termination because they cannot recruit enough participants, hindering medical advancements.
Solution
Ancora.ai is an AI-powered platform designed to streamline patient matching and recruitment for clinical trials. The platform analyzes patient medical profiles and preferences to identify relevant clinical trials, accelerating the enrollment process. By improving the precision of patient-trial matching, Ancora.ai helps clinical research organizations overcome recruitment bottlenecks and accelerate the development of new therapies. The platform aims to enhance the efficiency of clinical trials, ensuring that promising treatments reach patients faster.
Target Audience
The primary target audience includes clinical research organizations (CROs), pharmaceutical companies, and academic medical centers conducting clinical trials.
Features
- AI-driven patient-trial matching algorithm
- Secure data storage and HIPAA compliance
- Real-time tracking of patient enrollment progress
- Customizable search filters based on specific trial criteria
- Integration with electronic health record (EHR) systems